

CORRESPONDENCE

Open Access

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Roberto Mina¹, Angelo Belotti², Maria Teresa Petrucci³, Renato Zambello⁴, Andrea Capra¹, Giacomo Di Lullo¹, Sonia Ronconi⁵, Norbert Pescosta⁶, Mariella Grasso⁷, Federico Monaco⁸, Claudia Cellini⁹, Marco Gobbi¹⁰, Stelvio Ballanti¹¹, Paolo de Fabritiis¹², Maria Letizia Mosca-Siez¹³, Monia Marchetti^{14,15}, Anna Marina Liberati¹⁶, Massimo Offidani¹⁷, Nicola Giuliani¹⁸, Roberto Ria¹⁹, Pellegrino Musto^{20,21}, Alessandra Romano²², Pieter Sonneveld²³, Mario Boccadoro¹ and Alessandra Larocca¹

Disease progression in multiple myeloma (MM) can occur as a biochemical relapse (an increase in monoclonal component without end-organ damage) or as a clinical relapse (a proliferation of plasma cells accompanied by MM-related symptoms). The International Myeloma Working Group recommends that treatment should be initiated in the presence of a clinical relapse or in case of a rapid increase in the monoclonal component. The suitability of early treatment at the occurrence of biochemical relapse is still a matter of debate.

Although continuous therapy prolongs overall survival (OS) as compared to fixed-duration treatment^{1–3}, the salvage regimen bortezomib-dexamethasone (Vd, a standard of care and a platform for several triplet regimens) is usually administered for a fixed number of cycles^{4,5}.

Here we present the results of a multicenter, randomized phase II study aiming at evaluating efficacy and safety of either Vd maintenance or Vd retreatment at the occurrence of biochemical relapse as compared to standard observation in MM patients who received a bortezomib-based salvage regimen at relapse.

Patient eligibility, study design and statistical analysis are summarized in the Supplementary Appendix. Briefly, patients with relapsed/refractory (RR)MM (1–3 previous therapies) treated with a bortezomib-based regimen as last line of therapy without evidence of progression were randomized to: continuous treatment with subcutaneous bortezomib (1.3 mg/m²; days 1,15) and oral dexamethasone (20 mg; days 1, 2, 15, 16) every 28 days until progression (arm A); observation until clinical relapse as per standard of care (arm B); six 28-day cycles of subcutaneous bortezomib (1.3 mg/m²; days 1, 8, 15, 22) and oral dexamethasone (40 mg; days 1, 8, 15, 22) at the occurrence of biochemical relapse. The primary objective was to determine the time to progression (TTP), calculated as either the time from enrollment to biochemical relapse (TTBR) or the time from enrollment to clinical relapse (TTCR). This trial was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice and was registered at ClinicaTrials.gov ([NCT01913730](https://clinicaltrials.gov/ct2/show/study/NCT01913730)).

We analyzed 58 patients (median age: 70 years) enrolled from 21 Nov 2013 to 16 Mar 2017 and randomized to the three arms ($A = 15$, $B = 20$, $C = 23$, Supplementary Fig. S1; see Supplementary Table S1 for patient characteristics). On 22 Jul 2015, the protocol was amended: the arm A (Vd maintenance) was closed due to low speed of enrollment and the sample size was reduced.

Correspondence: Alessandra Larocca (alelarocca@hotmail.com)

¹Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

²Division of Hematology, Spedali Civili di Brescia, Brescia, Italy

Full list of author information is available at the end of the article

© The Author(s) 2020



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

In arm A, all patients (15/15) started Vd maintenance (median number of 11 maintenance cycles). In arm B, 18 patients (90%) experienced a biochemical relapse, in all cases followed by a clinical relapse, and started a subsequent line of therapy. In arm C, 21 patients had a biochemical relapse: 17 started therapy with Vd (median number of cycles: 6), while 4 patients did not (2 concomitant clinical relapses; 1 death; 1 consent withdrawal); 19 patients (83%) had a subsequent clinical relapse.

In arm A, the best response with Vd maintenance was at least a complete response (\geq CR) in 20% of patients, very good partial response (VGPR) in 13% and PR in 20% (Supplementary Table S2); 33% of patients improved by at least 1 category the response achieved with the previous therapy.

In arm C, Vd after the occurrence of a biochemical relapse resulted into an overall response rate (ORR) of

30% (PR, 6%; VGPR, 24%), with 82% of patients achieving at least a stable disease (SD), while 18% of patients progressed while on therapy (PD).

After a median follow-up of 41 months, TTBR was longer in patients receiving Vd maintenance (arm A, 18.2 months) than in patients who were observed until the occurrence of biochemical relapse (arm B, 4.9 months; arm C, 8.4 months; Fig. 1). TTCR was longer in patients treated with Vd maintenance (arm A, 22.1 months) or Vd at biochemical relapse (arm C, 20.3 months) than in patients under observation only (arm B, 9.5 months), being similar in the two experimental arms (A, C).

The median second progression-free survival (2nd PFS) was 20.5, 11.8 and 8.2 months in arms A, B and C, respectively.

A longer median OS was reported with Vd maintenance (arm A, 45.1 months), as compared to observation (arm B,




Fig. 1 Survival outcomes. Time to biochemical relapse (a), time to clinical relapse (b) and overall survival (c) in the examined population. TTBR time to biochemical relapse, TTCR time to clinical relapse, OS overall survival, ARM A bortezomib and dexamethasone until progression, ARM B observation until clinical relapse, ARM C early retreatment at biochemical relapse with bortezomib and dexamethasone.

Table 1 Treatment-related adverse events during the study treatment.

Adverse events	Arm A (n = 15) All grades (%)	Arm A (n = 15) Grade ≥ 3 (%)	Arm C (n = 17) All grades (%)	Arm C (n = 17) Grade ≥ 3 (%)
Hematologic				
At least 1 event	13	0	47	0
Anemia	7	0	29	0
Neutropenia	7	0	12	0
Thrombocytopenia	7	0	12	0
Non-hematologic				
At least 1 event	33	20	53	6
Cardiologic	0	0	6	0
Vascular	7	7	12	0
Infection	13	7	24	6
Nervous	20	7	18	0
Peripheral neuropathy	20	7	12	0
Gastrointestinal	13	0	6	0
Discontinuation due to adverse events	20	–	6	–

32.8 months) or Vd at biochemical relapse (arm C, 31.7 months), although this difference was not statistically significant.

Treatment was well tolerated, with limited grade 3–4, treatment-related adverse events (AEs; arm A 20%, arm B, 6%). Peripheral neuropathy (PN), mainly of grade 1–2, occurred in 20 and 12% of patients in arms A and C, respectively. Treatment discontinuation due to AEs was reported in 20 and 6% of patients in arms A and C, respectively (Table 1).

Continuous treatment is a standard approach in newly diagnosed (ND)MM and RRMM patients. In NDMM, continuous lenalidomide is a standard of care^{1,6}. Maintenance therapy with the oral proteasome inhibitor ixazomib proved to be an effective strategy in delaying disease progression after ASCT². Although bortezomib maintenance can extend PFS and OS in both transplant-eligible and -ineligible patients^{3,7}, bortezomib is usually administered for a limited number of cycles, primarily due to the risk of PN and the inconvenience for patients attending hospital for subcutaneous administration^{6–10}.

We hypothesized that the use of continuous Vd, in patients sensitive to a bortezomib-based salvage regimen as last line of therapy, would maintain, and even deepen, the previously achieved depth of response, ultimately

delaying disease progression in comparison with observation. In our study, the administration of Vd maintenance delayed by approximately 1 year TTBR (18.2 vs. 4.9 months) and TTCR (22.1 vs. 9.5 months), as compared to the control arm, in which patients were observed until the occurrence of clinical progression as per standard of care. Importantly, maintenance therapy did not negatively impact the efficacy of the subsequent lines of therapy, as shown by the longer median 2nd PFS (20.5 months) in the maintenance arm compared to that in the observation arm (11.8 months; Supplementary Table S3)^{1,2,7}. Vd maintenance was well tolerated, with a limited rate of PN (12% all grades; 6% grades 3–4). These findings are consistent with a phase 2 study that tested Vd maintenance in RRMM, reporting an ORR of 34.5% and a median TTP of 17 months¹¹. These results are of interest in the context of novel bortezomib-based combinations, such as daratumumab-Vd, in which bortezomib is administered only for 8 cycles⁵.

Salvage therapy is currently recommended in case of clinical relapse. However, this strategy is in contrast with the current definition of MM, which includes not only signs and symptoms of a clinically overt MM, but also markers predictive of an early imminent progression, prompting a therapeutic intervention in asymptomatic patients to prevent the development of MM-related comorbidities¹². In a Spanish trial, the median interval between biochemical and clinical relapse was 5.1 months¹³. Furthermore, there is evidence that biochemical relapse precedes the onset of a clinical relapse by several months¹³, and that early retreatment at biochemical relapse, rather than at clinical relapse, can delay disease progression and the onset of significant myeloma-related comorbidities, thus improving patients' quality of life¹⁴.

To our knowledge, this is the first randomized study that prospectively evaluated the efficacy and safety of early treatment at biochemical relapse in MM.

Early intervention with Vd induced disease stability or better in 82% of the treated patients and delayed clinical progression by ~11 months, as compared to observation until clinical relapse (20.3 vs. 9.5 months). These results confirmed the findings of previous studies. In the REBOUND trial, retreatment with a bortezomib-based regimen induced an ORR of 71% and a median PFS of 15 months. Retreatments with Vd was well tolerated, with a limited rate of PN¹⁵. The evidence generated by our study represents a proof-of-concept, suggesting that early retreatment in MM patients who previously benefited from a bortezomib-based therapy —with the aim of preventing MM-related anemia, bone lesions, renal failure and hypercalcemia — is feasible and effective.

Limitations of this study were the long enrollment time and the small sample size of enrolled patients, which limited the statistical significance of the comparisons. Also, the small sample size precluded subgroup analyses to understand whether a specific subset of patients, as those with a suboptimal response (<CR), could benefit more from continuous therapy or early retreatment with the same drug than those who had achieved CR (or vice versa). Despite these limitations, we were able to capture a clinically meaningful difference in TTBR and TTCR between the experimental arms (A, maintenance, and C, retreatment) and the control arm (observation, B). The study was specifically designed to compare each one of the experimental arms to the control arm, but not to one another. Consequently, we are unable to draw definite conclusions on the best bortezomib-based strategy to delay clinical relapse, whether a continuous, gentler approach after the induction phase or a close observation followed by early bortezomib retreatment at the occurrence of biochemical relapse, in order to allow patients a treatment-free period.

In conclusion, we demonstrated that, in RRMM treated with a bortezomib-based salvage therapy, maintenance therapy with Vd or early retreatment with Vd at the occurrence of biochemical relapse were safe and effective strategies to delay clinical progression without negatively affecting the efficacy of subsequent lines of therapy.

Acknowledgements

We thank all the patients who participated in the study, the nurses Sonia Grandi and Mario Gorla, the data managers Debora Caldarazzo and Alessia Gribaudo, and Ugo Panzani from the Torino site.

Author details

¹Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. ²Division of Hematology, Spedali Civili di Brescia, Brescia, Italy. ³Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. ⁴Padova University School of Medicine, Hematology and Clinical Immunology, Padova, Italy. ⁵Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. ⁶Reparto di Ematologia e Centro TMO, Ospedale Centrale, Bolzano, Italy. ⁷S.C. Ematologia, Azienda Ospedaliera Santa Croce - Carle, Cuneo, Italy. ⁸Dipartimento di Ematologia e Medicina Trasfusionale, Azienda Ospedaliera 'Ss. Antonio e Biagio e Cesare Arrigo', Alessandria, Italy. ⁹U. O.C. EMATOLOGIA, Ospedale Santa Maria delle Croci, Ravenna, Italy. ¹⁰Clinical Hematology, Ospedale Policlinico S. Martino, Istituto di Ricovero e Cura a Carattere Scientifico, Genoa, Italy. ¹¹Ematologia con TMO, Ospedale Santa Maria della Misericordia di Perugia, Perugia, Italy. ¹²Hematology, St. Eugenio Hospital, University Tor Vergata, Rome, Italy. ¹³Division of Hematology, Department of Medicine, Ospedale degli Infermi, Biella, Italy. ¹⁴Day Hospital Ematologico, Ospedale Cardinal Massaia, Asti, Italy. ¹⁵Unità di Ematologia, Azienda Sanitaria Ospedaliera 'Ss. Antonio e Biagio e Cesare Arrigo', Alessandria, Italy. ¹⁶Università degli Studi di Perugia - Azienda Ospedaliera Santa Maria, Terni, Italy. ¹⁷Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy. ¹⁸Dipartimento di Medicina e Chirurgia, Università di Parma, Parma, Italy. ¹⁹Internal Medicine "G. Baccelli", Department of Biomedical Science, University of Bari "Aldo Moro" Medical School, Bari, Italy. ²⁰Hematology, IRCCS CROB, Rionero in Vulture (Pz), Italy. ²¹Unit of Hematology and Stem Cell Transplantation, AOU Policlinico Giovanni XXIII, School of Medicine, Aldo Moro University, Bari, Italy. ²²Division of Hematology, AOU Policlinico-OVE, University of Catania, Catania, Italy.

²³Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands

Author contributions

R.M., A.L. and M.B. conceived and designed the work that led to the submission. All the authors collected the data and interpreted the results. R.M., G.D.L. and A.L. drafted the first version of the manuscript. A.C. performed the statistical analysis. All the authors revised the manuscript and approved the final version. All the authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of interest

R.M. has received honoraria from Amgen, Celgene, Takeda, and Janssen; has served on the advisory boards for Janssen. A.B. has served on the advisory boards for Janssen, Celgene, and Amgen. M.T.P. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; has served on the advisory boards for Bristol-Myers Squibb, Celgene, Janssen, Sanofi, and Takeda. R.Z. has served on the advisory boards for Janssen and Celgene. S.B. has received grants from Janssen and Celgene for participating as speaker in meetings. M.M. has received financial support (advisory board, consultant, invited speech) from Gilead, Takeda, AbbVie, Amgen, Celgene, Janssen, Pfizer, Novartis, and Sanofi. A.M.L. has received personal fees from Incyte; has received research funding from Novartis, Janssen, AbbVie, Roche, Celgene, Amgen, Bristol-Myers Squibb, Takeda, Incyte, Pfizer, Beigene, Oncopetites, Verastem, Karyopharm, Archigen, Biopharma, Debiopharm, Morphosys, Fibrogen, and Onconova. M.O. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; has served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. N.G. has received honoraria from Bristol-Myers Squibb, Celgene, and Janssen; has served on the advisory boards for Amgen, Celgene, Takeda, Janssen; has received research funding from Celgene, Janssen; has received sponsorship for clinical trials from GlaxoSmithKline, Janssen, and Takeda. R.R. has served on the speakers' bureau for Bristol-Myers Squibb, CSL Behring, Celgene, Italfarmaco, and Janssen Cilag; has undertaken consultancy for Bristol-Myers Squibb, CSL Behring, Celgene, Italfarmaco, Janssen Cilag, and Octapharma. P.M. has received personal fees from Amgen, Novartis, BMS, Celgene, Janssen, and Takeda. P.S. has served on the advisory boards for Amgen, Celgene, Genenta, Janssen, Seattle Genetics, Takeda, and Karyopharm. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. A.L. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and GSK; has served on the advisory boards for Bristol-Myers Squibb, Celgene, Janssen, and Takeda. The other authors declare no competing financial interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (<https://doi.org/10.1038/s41408-020-0326-1>).

Received: 16 March 2020 Revised: 27 April 2020 Accepted: 30 April 2020
Published online: 18 May 2020

References

- McCarthy, P. L. et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. *J. Clin. Oncol.* **35**, 3279–3289 (2017).
- Dimopoulos, M. A. et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet* **393**, 253–264 (2019).
- Sonneveld, P. et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. *J. Clin. Oncol.* **30**, 2946–2955 (2012).

4. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N. Engl. J. Med.* **352**, 2487–98. (2005).
5. Palumbo, A. et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N. Engl. J. Med.* **375**, 754–766 (2016).
6. Benboubker, L. et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. *N. Engl. J. Med.* **371**, 906–917 (2014).
7. Palumbo, A. et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. *J. Clin. Oncol.* **32**, 634–640 (2014).
8. San-Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N. Engl. J. Med.* **359**, 906–917 (2008).
9. Mateos, M.-V. et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom. *Lancet Oncol.* **11**, 934–941 (2010).
10. Moreau, P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **28**, iv52–iv61 (2017).
11. Benevolo, G. et al. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. *Cancer* **117**, 1884–1890 (2011).
12. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol.* **15**, e538–e548 (2014).
13. Lopez, A. et al. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. *Leuk Res. Rep.* **4**, 64–69 (2015).
14. Katodritou, E. et al. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. *Ann. Hematol.* **97**, 1671–1682 (2018).
15. Musto, P. et al. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life Bortezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study). *Ann. Hematol.* **98**, 361–367 (2019).